
Guided Therapeutics, Inc.
GTHPOTCHealthcare● Active
$0.20
+$0.00(+0.00%)
Market Cap$15340000
P/E Ratio—
52W High$0.54
52W Low$0.123
Guided Therapeutics, Inc. (GTHP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GTHP · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.77M | $0.01M | $0.10M | $0.01M | $0.08M |
| Cost of Revenue | $0.20M | $0.01M | $0.06M | $0.08M | $0.06M |
| Gross Profit | $0.57M | $0.00M | $0.04M | ($0.07M) | $0.02M |
| Gross Margin %(computed) | 74.45% | 28.57% | 36.73% | -523.08% | 24.69% |
| Operating Expenses | |||||
| R&D Expenses | $0.47M | $0.53M | $0.23M | $0.08M | $0.07M |
| G&A Expenses | $2.31M | $1.30M | $3.00M | $3.01M | $2.17M |
| Total Operating Expenses | $2.94M | $2.11M | $3.49M | $3.27M | $2.38M |
| Operating Income | ($2.37M) | ($2.11M) | ($3.46M) | ($3.33M) | ($2.36M) |
| Operating Margin %(computed) | -309.26% | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.01M | $0.00M | $0.00M |
| Interest Expense | $0.62M | $0.38M | $0.28M | $0.58M | $1.15M |
| Income Before Tax | ($3.20M) | ($2.42M) | ($3.49M) | ($4.34M) | ($2.07M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($3.20M) | ($2.42M) | ($3.49M) | ($4.34M) | ($2.07M) |
| Net Margin %(computed) | -416.69% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.04 | $-0.05 | $-0.07 | $-0.15 | $-0.18 |
| Wtd Avg Shares | 78.41M | 57.34M | 51.13M | 32.51M | 13.38M |
| EBITDA | ($2.47M) | ($1.94M) | ($3.13M) | ($3.69M) | ($0.92M) |
| EBITDA Margin %(computed) | -322.29% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Guided Therapeutics, Inc. data
About Guided Therapeutics, Inc. (GTHP) Income Statement
Guided Therapeutics, Inc. (GTHP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GTHP reported revenue of $0.00B, gross profit of $0.00B (gross margin 74.45%), and net income of ($0.00B) — a net profit margin of -416.69%.
Frequently asked questions
GTHP · 4 questionsGuided Therapeutics, Inc. (GTHP) reported revenue of $0.00B for 2025, up 10857.1% year-over-year.
GTHP revenueGTHP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09